Emerging targets for anticancer vaccination: PD-1

PD‐1 specific ‘Blocking’ antibodies that deplete PD‐1+ T cells present An inconvenient variable in pre‐clinical immunotherapy experiments

(2021) Fanny Polesso et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

First prototype checkpoint inhibitor B-cell epitope vaccine (PD1-Vaxx) en route to human Phase 1 clinical trial in Australia and USA: exploiting future novel synergistic vaccine combinations

(2021) Linlin Guo et al.   BRITISH JOURNAL OF CANCER

Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer—Results from Phase Ib Trial IMU.ACS.001

(2021) Ursula Wiedermann et al.   CLINICAL CANCER RESEARCH

PD‐1 blocking antibodies moonlighting as killers

(2021) Judith Leitner et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

FDA approves 100th monoclonal antibody product

(2021) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics

(2020) Vinayaka Kotraiah et al.   Frontiers in Immunology

A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors

(2020) Joshua Tobias et al.   Frontiers in Immunology

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence

(2020) Raju K. Vaddepally et al.   Cancers

Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy

(2020) Wenjie Zhai et al.   Science China-Life Sciences

Advances on immune-related adverse events associated with immune checkpoint inhibitors

(2020) Yong Fan et al.   Frontiers of Medicine

The Unique Pharmacometrics of Small Molecule Therapeutic Drug Tracer Imaging for Clinical Oncology

(2020) Mark P. S. Dunphy et al.   Cancers

Fragments of gD Protein as Inhibitors of BTLA/HVEM Complex Formation - Design, Synthesis, and Cellular Studies

(2020) Katarzyna Kuncewicz et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A rationally designed peptide antagonist of the PD-1 signaling pathway as an immunomodulatory agent for cancer therapy

(2019) Pottayil G Sasikumar et al.   MOLECULAR CANCER THERAPEUTICS

Development of the Inhibitors that Target the PD-1/PD-L1 Interaction—A Brief Look at Progress on Small Molecules, Peptides and Macrocycles

(2019) Guzik et al.   MOLECULES

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

(2019) Filipe Martins et al.   Nature Reviews Clinical Oncology

CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?

(2019) Bogdan Musielak et al.   MOLECULES

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling

(2019) Annika De Sousa Linhares et al.   Scientific Reports

Comprehensive in vitro characterization of PD-L1 small molecule inhibitors

(2019) Aravindhan Ganesan et al.   Scientific Reports

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer

(2019) Weiting Qin et al.   Frontiers in Immunology

Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy

(2019) Hao Liu et al.   Journal for ImmunoTherapy of Cancer

Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?

(2018) Markella Konstantinidou et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction

(2018) Rebecca J. Boohaker et al.   CANCER LETTERS

Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy

(2018) Kui Li et al.   JOURNAL OF DRUG TARGETING

Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events

(2018) Heinz Läubli et al.   Journal for ImmunoTherapy of Cancer

Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways

(2018) Pottayil G. Sasikumar et al.   BIODRUGS

Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1

(2017) Katarzyna Guzik et al.   JOURNAL OF MEDICINAL CHEMISTRY

Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2

(2017) Krzysztof M. Zak et al.   STRUCTURE

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells

(2017) Lukasz Skalniak et al.   Oncotarget

Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy

(2017) Chunlin Li et al.   Cancer Immunology Research

Library-based display technologies: where do we stand?

(2016) Asier Galán et al.   Molecular BioSystems

Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor

(2016) Qiao Li et al.   Oncotarget

PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine

(2016) Shamaila Munir Ahmad et al.   OncoImmunology

A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors

(2015) T. W. Chen et al.   ANNALS OF ONCOLOGY

From Peptides to Small Molecules: An Intriguing but Intricated Way to New Drugs

(2013) P. Scognamiglio et al.   CURRENT MEDICINAL CHEMISTRY

Cancer immunotherapy – revisited

(2011) W. Joost Lesterhuis et al.   NATURE REVIEWS DRUG DISCOVERY

mAbs

(2010) Pablo A. Scolnik   mAbs

Therapeutic antibodies: successes, limitations and hopes for the future

(2009) Patrick Chames et al.   BRITISH JOURNAL OF PHARMACOLOGY

Mechanisms of costimulation

(2009) Arlene H. Sharpe   IMMUNOLOGICAL REVIEWS

Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

(2008) G. G. Kenter et al.   CLINICAL CANCER RESEARCH

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways

(2008) Brian T. Fife et al.   IMMUNOLOGICAL REVIEWS